Clinical trials: Intra Uterine Growth Retardation
Intrauterine Growth Restriction
IUGR; Cause and Relationship
Intrauterine growth restriction (IUGR) is a pregnancy complication in about 3-5% of all pregnancies in Sweden. IUGR fetuses are at high risk of morbidity and death.
- Trial name
- NCT05142644
- Testing
- ultrasound
- Where
- Sweden
- Volunteers
- 80,000 people
- Sponsor
- Karolinska Institutet
Pre-eclampsia, Intra-uterine Growth Retardation
EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction
The purpose of this study is to assess the potential prognostic value of seric concentrations of EG-VEGF for Pre-eclampsia and/or intrauterine growth restriction and will allow checking whether plasma levels of EG-VEGF at 14-18…
- Trial name
- EGEVE (NCT01490489)
- Testing
- blood sample and doppler Ultrasound of uterine arteries
- Where
- France
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Intrauterine Growth Restriction
Intra Uterine Growth Restriction
Intrauterine growth restriction (IUGR) is associated with an increase in perinatal mortality and morbidity, as well as longer-term neurological, cognitive, cardiovascular and endocrine complications.
- Trial name
- IUGR (NCT03866863)
- Testing
- Intrauterine growth restriction (IUGR)
- Where
- France
- Volunteers
- 31,052 people
- Sponsor
- Hospices Civils de Lyon
Intra Uterine Growth Retardation
The Relationship Between Second Trimester Placental Growth Factor Level and Fetal Growth Restriction
Type of the study: A prospective observational study Study settings: The study will be conducted at Ain Shams University Maternity Hospital, Obstetrics and Gynecology Department, Faculty of medicine over a period of six month…
- Trial name
- NCT03350399
- Testing
- placenta growth factor
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- amera mohamed
Intra-Uterine Growth Retardation
Sildenafil in Sever Intrauterine Growth Retardation
Severe fetal growth restriction (FGR) complicates approximately 0.4% of pregnancies and severely increases the risk of perinatal morbidity and mortality.Sildenafil citrate may offer a potential therapeutic strategy to improve…
- Trial name
- IUGR (NCT03153215)
- Testing
- treatment
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Beni-Suef University
Pregnancy, Primiparity
MorbiMortality Amelioration in Preeclamptic Primiparas Study. MoMA Pre Prim Study
The purpose of this study is to determine whether close monitoring of patients with a high sFlt1 plasma level between 25 and 28 weeks of gestation (i.e.
- Conditions
- Pregnancy, Primiparity, Hypertension, Preeclampsia
- Trial name
- MOMA (NCT00763672)
- Testing
- Transmission of sFlt-1 results to the investigator, No transmission of the sFlt-1 results to the investigator
- Where
- France
- Volunteers
- 1,040 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Preeclampsia, Preterm Birth
Prediction of Preeclampsia and Other Pregnancy Complications Following Combined Iterative Screening
Preterm birth (PTB), preeclampsia (PE), fetal growth restriction (FGR) and intra-uterine fetal death (IUFD) constitutes the main causes of perinatal morbidity and mortality and are called "Great Obstetrical Syndromes".
- Conditions
- Preeclampsia, Preterm Birth, Fetal Growth Restriction, Intra Uterine Fetal Death
- Trial name
- PREDICTION2 (NCT03067298)
- Where
- Canada
- Volunteers
- 805 people, healthy volunteers welcome
- Sponsor
- Emmanuel Bujold
Preeclampsia, Severe Preeclampsia
Pre-Eclampsia And Growth Restriction: a Longitudinal Study
Preeclampsia may have several causes leading to different characteristics of the pathology. Differentiation between the "type of preeclampsia" would help to treat patients more accurately.
- Conditions
- Preeclampsia, Severe Preeclampsia, Fetal Growth Restriction, Preterm Birth
- Trial name
- PEARL (NCT02379832)
- Where
- Canada
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- CHU de Quebec-Universite Laval
Preeclampsia, IUGR
Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler
Second trimester homocysteine \& uterine artery doppler will be assessed\& the cases will be followed up till delivery for development of preeclampsia, IUGR(intra-uterine growth retardation) \& other obstetric complications.
- Trial name
- NCT02541110
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Kasr El Aini Hospital
Children Born With Serious Intra-uterine Growth Retardation
Saizen in Intra-uterine Growth Retardation
Study of safety of Saizen® in children born with serious intra-uterine growth retardation (IUGR) treated to final height. An open, phase III study involving 17 centers in France.
- Trial name
- NCT01400698
- Testing
- Saizen® A, Saizen® B, Observation only
- Volunteers
- 91 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Prenatal Care, Premature Birth
Biological Markers of Disease in the Prediction of Preterm Delivery, Preeclampsia and Intra-Uterine Growth Retardation: A Longtitudinal Study
Preterm delivery, preeclampsia and intrauterine growth restriction are leading causes of perinatal morbidity and mortality. Efforts to treat these syndromes have not been effective, most likely becuase these obstetric…
- Trial name
- NCT00340899
- Where
- Chile
- Volunteers
- 19,134 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Intra Uterine Growth Retardation
L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial (L Arginine in IUGR)
Although there is a strong rationale to supplement gravid patients suffering intrauterine growth restriction (IUGR) or preeclampsia with Arginine or other nitric oxide donors, evidence in the literature has been inconclusive.
- Trial name
- NCT00549575
- Testing
- L ARG
- Where
- France
- Volunteers
- 44 people
- Sponsor
- Nantes University Hospital
Preeclampsia, Severe Preeclampsia
First-trimester Prediction of Preeclampsia
Preeclampsia is a complication of pregnancy related to adverse maternal and neonatal outcomes, including fetal growth restriction and perinatal death.
- Conditions
- Preeclampsia, Severe Preeclampsia, Fetal Growth Restriction, Preterm Birth
- Trial name
- PREDICTION (NCT02189148)
- Where
- 4 sites in Canada
- Volunteers
- 7,554 people, healthy volunteers welcome
- Sponsor
- CHU de Quebec-Universite Laval
Intra-uterine Growth Delay
Effects (Long Term Analysis) of an Hyperproteinic Nutrition on Neonates With Intra-uterine Growth Delay : a Prospective, Multicentric , Randomized, Double Blind Study ("Proneonat")
Neonates with intra-uterine growth delay represent more than 2% of the 800 000 annual births in France. Studies have shown that milks enriched with protein allow to accelerate newborns growth.
- Trial name
- Proneonat (NCT00764179)
- Testing
- milk enriched in proteins (2.15 g/100ml), milk with normal protein concentration (1.45g/100ml)
- Where
- France
- Volunteers
- 93 people
- Sponsor
- Nantes University Hospital
Growth Disorders, Intrauterine Growth Retardation
Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation
To evaluate the effect of continuous and intermittent administration of Genotonorm on stature in short prepubertal children with intra-uterine growth retardation
- Trial name
- NCT01073605
- Testing
- Genotonorm
- Where
- 31 sites in France
- Volunteers
- 208 people
- Sponsor
- Pfizer
Intrauterine Growth Restriction, Fetal Growth Restriction (FGR)
Diagnostic Value of sFlt-1/PlGF Ratio for the Etiology of Intra Uterine Growth Restriction - ANGIOPAG
The main aim of this project is to determine the Placental Growth Factor and Vascular Endothelial Growth Factor ratio's performance (sFlt-1/PlGF) for the etiological diagnosis of vascular Intrauterine growth restriction (IUGR)…
- Trial name
- ANGIOPAG (NCT05151289)
- Testing
- Blood test at time of inclusion for sFlt-1/PlGF ratio, Follow-up blood test 2 to 4 weeks after inclusion, Placenta analysis for all included patients, even in case of normal birthweight
- Where
- France
- Volunteers
- 167 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris